<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy

<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy

Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated <i>TP53</i> somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with seco...

Full description

Bibliographic Details
Main Authors: Francesco Graziano, Nicholas W. Fischer, Irene Bagaloni, Maria Di Bartolomeo, Sara Lonardi, Bruno Vincenzi, Giuseppe Perrone, Lorenzo Fornaro, Elena Ongaro, Giuseppe Aprile, Renato Bisonni, Michele Prisciandaro, David Malkin, Jean Gariépy, Matteo Fassan, Fotios Loupakis, Donatella Sarti, Michela Del Prete, Vincenzo Catalano, Paolo Alessandroni, Mauro Magnani, Annamaria Ruzzo
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
gastric cancer
<i>TP53</i>
Ramucirumab
Paclitaxel
angiogenesis
Online Access:https://www.mdpi.com/2072-6694/12/8/2049

Internet

https://www.mdpi.com/2072-6694/12/8/2049

Similar Items